◼ Archived
Business
First personalised cancer vaccine cuts risk of disease returning in major trial
A personalized mRNA cancer vaccine developed by Moderna and Merck cuts melanoma recurrence or death risk by 42%.
Mrna
43 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning
Moderna stock extends recent market losses following the release of trial data concerning a novel mRNA melanoma vaccine.
◼ Archived
Business
Breakthrough vaccine for the deadliest skin cancer cut risk by almost half
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Moderna stock crashes as leaked melanoma data threatens its record August rally
Personalized mRNA cancer vaccine data shows significant reduction in melanoma recurrence and death rates.
◼ Archived
Health
Moderna (MRNA) Starts Late Stage Trial For mRNA Bird Flu Vaccine
Moderna has initiated a late-stage trial for an mRNA bird flu vaccine amid broader developments in influenza immunization options.
◼ Archived
Health
HealthLink: You're an older adult and need a flu shot. Which one to get?
Older adults and pharmacies navigate new mRNA options and availability questions for the current flu season.
◼ Archived
Health
Head-to-head comparison of three mRNA vaccines reveals differences in their stability in human blood
Recent head-to-head comparisons show three mRNA vaccines behave differently and stability varies in human blood.
◼ Archived
Health
Cancer Vaccines Are the N.I.H.’s Next ‘Big Bet’
Cancer vaccines emerge as a major focus for the N.I.H. through a newly announced public-private partnership.
◼ Archived
Business
Novartis takes rights to Abogen’s mRNA T cell engager for $575M upfront
Novartis secures the rights to Abogen’s mRNA T cell engager in a massive $575 million upfront transaction.
◼ Archived
Business
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
Novartis has agreed to a massive new mRNA drug deal with Chinese startup Abogen worth up to $7.8 billion.
◼ Archived
Health
Exclusive | She was ready to die. Now she’s in remission
New developments in personalized mRNA cancer vaccines show promise for melanoma and breast cancer, though hurdles in public perception remain.
◼ Archived
Health
New mRNA flu vaccine for adults over 50 is 'more effective,' UW Medicine says
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Moderna CEO’s Realistic Approach to Innovation
Moderna shares surge and track toward top September S&P 500 performance as markets eye upcoming clinical data.
◼ Archived
Business
Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Dear Doctor: Is the new flu vaccine better enough to justify waiting for it?
The US has seen the launch of Moderna's mFlusiva, the first approved mRNA flu vaccine designed for specific older adult populations.
◼ Archived
Health
Cancer Vaccines Market Anticipates Impressive Growth Trajectory at a CAGR of 36% During the Forecast Period (2026-2036)
Recent coverage examines the growing cancer vaccines market alongside Phase 3 mRNA vaccine results and personalised medicine strategies.
◼ Archived
Health
Flu season is coming: What to know about new vaccine, when to get your shot and more
A newly approved mRNA flu shot for adults 50+ is rolling out at CVS, Walgreens and local pharmacies as the 2026 flu season approaches.
◼ Archived
Business
🔮 fades ✓
Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?
Moderna and Merck trial data sparks debate over whether a personalized medicine revolution is beginning.
◼ Archived
Health
🔮 fades ✗
What to know about the new mRNA flu vaccine
Health coverage highlights FDA approval of Moderna's new mRNA flu vaccine and emerging studies on broader antibody responses.
◼ Archived
Business
🔮 holds ✗
Personalized mRNA cancer vaccines offer new hope. We explain
Personalized mRNA cancer vaccines are gaining momentum following Phase III success in melanoma and expanded global clinical trials.
◼ Archived
Business
🔮 fades ✗
ARPA-H awards $125M for manufacturing custom RNA therapies on demand
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
GSK catches phase 3 fever after mRNA flu vaccine beats standard shots
GSK advances its mRNA flu vaccine candidate to phase 3 trials following successful mid-stage performance data.
◼ Archived
Business
🔮 fades ✓
There’s a big change for this year’s flu shot: When should you be vaccinated?
GSK is advancing a new mRNA flu vaccine to Phase III trials after the candidate outperformed standard vaccinations in earlier testing.
◼ Archived
Business
🔮 fades ✓
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
BioNTech and Genentech have terminated a phase 2 mRNA colorectal cancer vaccine trial after safety reviews revealed more deaths than in the control group.
◼ Archived
Business
🔮 fades ✓
There’s a new type of flu vaccine for older adults this year. Can you get it?
The FDA has approved Moderna's mRNA-based flu vaccine, marking a shift in immunization technology for older adults.
◼ Archived
Business
🔮 fades ✓
It now seems possible to vaccinate against cancer
Advancements in mRNA technology are driving the development of cancer vaccines, specifically targeting melanoma and expanding medical breakthroughs.
◼ Archived
Business
🔮 fades ✓
Moderna, Merck breakthrough could usher in wave of cancer vaccines
11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Science
🔮 fades ✓
New lipid nanoparticle delivers capped circular RNA for longer-lasting gene expression
5 news sources are covering this Science story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Moderna and Merck’s mRNA Melanoma Vaccine Looks Like a Game Changer
Moderna and Merck's mRNA melanoma vaccine is drawing significant attention as a potential game changer according to recent coverage.
◼ Archived
Business
🔮 holds ✓
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
Moderna and Merck report success in a late-stage melanoma trial for their personalized mRNA cancer vaccine.
◼ Archived
Health
🔮 fades ✓
Mercy Health doctors excited about new FDA-approved flu vaccine
An mRNA flu shot becomes available in the United States for the first time, according to Smithsonian Magazine.
◼ Archived
Health
🔮 fades ✓
What To Know About The New, More Effective Flu Shot For Adults 50 And Over
The first mRNA-based flu vaccine has been approved in the US, specifically targeting adults aged 50 and over for improved effectiveness.
◼ Archived
Health
🔮 fades ✓
The US Just Approved Its First mRNA Flu Vaccine. Is This a New Era?
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✗
The strange reason flu shots have been so hard to improve
The U.S. has approved the first-ever mRNA flu vaccine from Moderna, though concerns over side effects may impact public adoption.
◼ Archived
Health
🔮 fades ✗
FDA approves 1st mRNA flu shot, from Moderna
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 holds
Targeting Allele-Specific Faulty MRNA In SCNA2 Mutation Patients
Personalized gene therapy using bespoke ASOs has enabled a teen with SCN2A-related epileptic encephalopathy to walk independently for the first time.
◼ Archived
Health
🔮 fades
An HIV vaccine is within reach thanks to mRNA
Advancements in mRNA technology have brought the development of an HIV vaccine closer to reality through new neutralizing antibody responses.
◼ Archived
Health
🔮 fades
Huge Survey Finds the Truth About What mRNA Vaccines Do to the Human Body
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
FDA advisors unanimously vote to approve Moderna’s mRNA after agency drama
An FDA advisory committee has unanimously recommended the approval of Moderna's mRNA influenza vaccine for older adults.
◼ Archived
Business
🔮 fades
FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
An FDA advisory committee has unanimously backed Moderna's mRNA-based flu vaccine, marking a significant development for the technology.
◼ Archived
Business
🔮 fades
The Surprising FDA View That Sent Moderna Stock Flying
Moderna stock prices increased following positive feedback from the FDA regarding the company's mRNA influenza vaccine candidate.